Indantadol HCl

Catalog No: #S08724

Package Size: #S08724-1 1 mg #S08724-2 10 mg #S08724-3 100 mg #S08724-4 25 mg #S08724-5 5 mg #S08724-6 50 mg #S08724-7 500 mg

Orders: order@signalwayantibody.com
Support: tech@signalwayantibody.com

Description

Product Name	Indantadol HCl
Other Names	Indantadol;Indantadol HCl;Indantadol hydrochloride;GT 3381;GT3381;MAO;NMDA;CHF3381;CHF-3381;CHF 3381;CNP 3381;CNP3381;CMP 3381;CMP3381;V3381;V 3381
Calculated MW	226.7
Storage	Powder: -20°C for 3 years . In solvent: -80°C for 1 year . Shipping with blue ice.

Application Details

ε ε-• εΌ• :C11H15ClN2OSmile:Cl.O=C(N)CNC1CC=2C=CC=CC2C1DMLε• ·:MFCD09840800ηΊ—ε΄¦:98.24%ζΊΆθ§£ε΄¦:DMSO:50 mg/mL (220.56 mM)δ½ ε ζ΄»ζ §:In a human heat-capsaicin-induced pain model, Indantadol HCl at a dose of 500 mg effectively reduced the area of secondary hyperalgesia to 67%. Indantadol HCl undergoes extensive liver metabolism, withthe formation of two major metabolites - CHF-3567 and 2-aminoindane. The drug is excreted in urine partially as the parent compound, but mostly as CHF-3567. The tolerability profile of Indantadol HCl at single doses up to 600 mg and twice-daily doses up to 400 mg in clinical trials was significantly more favorable than for other NMDA antagonists. Most side effects have been observed to be mild, and include dizziness and asthenia. Indantadol HCl is currently in phase II clinical trials in patients with diabetic peripheral neuropathic pain.[1]δΩ‘ε• ·ι θ·—:δ»£θ°'|η η»• η§ ε-¦|η η»• η§ ε-¦ι• Άη Ή:MAO|NMDAR

Note: This product is for in vitro research use only and is not intended for use in humans or animals.